Xolair (Omalizumab) is a recombinant DNA-derived humanized monoclonal antibody that selectively binds to human immunoglobulin E (IgE)1
Xolair is indicated as add-on therapy:
For the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to H1 antihistamine treatment1
Dosing and administration1
SVG
| The recommended dose is 300 mg every 4 weeks by subcutaneous injection. |
Xolair API
Xolair API
References
Xolair® 150 mg powder and solvent for solution for injection Ministry of health (MOH) approved leaflet. approval date: 26/10/2020.
Approved by Egyptian Drug Authority: HBF0424OA4702/092025. Invalidation date: 03/09/2026.
Kindly report any violated online promotional, educational and awareness material not having this message to The General administration for Regulation of Marketing & Advertising Materials at: www.edaegypt.gov.
Image
|
HBF0424OA4702/092025 |
Adverse Events Reporting We encourage using the following Electronic reporting tool for reporting into the safety database directly: |